|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
ARTN and TWIST1 synergize to produce a worse outcome in ER-MC and combined inhibition of ARTN and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) may therefore provide a novel therapeutic strategy in this subtype of mammary carcinoma.
|
22060274 |
2011 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This Snail1-Twist1 temporal and spatial cooperation was also observed in vivo during human breast cancer progression to metastasis.
|
22006115 |
2011 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Metformin treatment dynamically regulated the CD44(pos)CD24(neg/low) breast cancer stem cell immunophenotype, transcriptionally reprogrammed cells through decreased expression of key drivers of the EMT machinery including the transcription factors ZEB1, TWIST1 and SNAI2 (Slug) and the pleiotrophic cytokines TGFβs, and lastly impeded the propensity of breast cancer stem cells to form multicellular "microtumors" in non-adherent and non-differentiating conditions (i.e., "mammospheres").
|
20890129 |
2010 |
|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
To investigate the prognostic relevance of disseminated tumor cells (DTCs) in bone marrow (BM) assessed by a multimarker mRNA panel consisting of TWIST1, cytokeratin 19 (CK19) and human mammaglobin A (hMAM) mRNA, in patients with early breast cancer.
|
20920982 |
2010 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer risk is not increased in individuals with TWIST1 mutation confirmed Saethre-Chotzen syndrome: an Australian multicenter study.
|
19373776 |
2009 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our studies show the diverse responses to Adriamycin treatment in cells at different phases, suggest an unrecognized role of EMT in regulating MDR and invasion, and show the efficacy of Twist1 RNA interference in Adriamycin-based chemotherapies for breast cancer.
|
19336515 |
2009 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Median methylation ratios observed in breast cancer (n = 100) were significantly higher than those observed in benign breast tissues for five of six genes (TWIST, HIN-1, RASSF1A, RARbeta2 and APC).
|
19829046 |
2009 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This indicates that although TWIST1 CpG methylation is useful as a biomarker in breast cancer diagnosis, there is no direct correlation with TWIST1 expression.
|
19064546 |
2008 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Additional studies are, however, necessary to reveal the mechanism by which TWIST1 may predispose to early onset breast cancer in Saethre-Chotzen patients.
|
17437280 |
2007 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
As proof-of-principle applications, we established duplex assays to examine the FMR1 promoter in individuals with fragile-X syndrome and the SNRPN promoter in individuals with Prader-Willi syndrome or Angelman syndrome, and a multiplex assay to simultaneously detect hypermethylation of seven genes (ID4, APC, RASSF1A, CDH1, ESR1, HIN1 and TWIST1) in breast cancer cell lines and tissues.
|
17998253 |
2007 |
|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Most transcripts identified, including TWIST1, were not expressed in enriched populations of bone marrow from normal volunteers, suggesting that this expression profile reflects a signature of breast cancer bone marrow micrometastases that persist after chemotherapy.
|
17785550 |
2007 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis of 130 primary breast carcinomas indicates positive correlations between non-nuclear EGFR and TWIST and between phosphorylated STAT3 and TWIST.
|
17909010 |
2007 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We evaluated the methylation of RARbeta2, CDH1, ER, BRCA1, CCND2, p16 and TWIST in 193 breast carcinomas.
|
16029926 |
2006 |
|
Breast Carcinoma
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
We examined the distribution and expression of these three molecules together with the methylation of the Twist gene promoter in human breast cancer to elucidate their clinical significance.
|
15864483 |
2005 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|